These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 18199894

  • 1. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
    Lasseter KC, Shaughnessy L, Cummings D, Pezzullo JC, Wargin W, Gagnon R, Oliva J, Kosutic G.
    J Clin Pharmacol; 2008 Feb; 48(2):193-202. PubMed ID: 18199894
    [Abstract] [Full Text] [Related]

  • 2. The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial.
    Popescu I, Fleshner PR, Pezzullo JC, Charlton PA, Kosutic G, Senagore AJ.
    Dis Colon Rectum; 2010 Feb; 53(2):126-34. PubMed ID: 20087086
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA.
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
    Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A.
    Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
    [Abstract] [Full Text] [Related]

  • 8. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin.
    Mulchahey JJ, Goldwater DR, Zemlan FP.
    Life Sci; 2004 Aug 27; 75(15):1843-56. PubMed ID: 15302228
    [Abstract] [Full Text] [Related]

  • 9. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
    Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J.
    J Clin Pharmacol; 2008 Apr 27; 48(4):418-27. PubMed ID: 18258750
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
    Rodríguez CA, Azie NE, Adams G, Donaldson K, Francom SF, Staton BA, Bombardt PA.
    J Clin Pharmacol; 2004 Mar 27; 44(3):276-83. PubMed ID: 14973308
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.
    Clin Ther; 2008 Mar 27; 30(3):513-27. PubMed ID: 18405789
    [Abstract] [Full Text] [Related]

  • 13. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
    Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M.
    Diabetologia; 2002 Feb 27; 45(2):195-202. PubMed ID: 11935150
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study.
    Ejskjaer N, Dimcevski G, Wo J, Hellström PM, Gormsen LC, Sarosiek I, Søfteland E, Nowak T, Pezzullo JC, Shaughnessy L, Kosutic G, McCallum R.
    Neurogastroenterol Motil; 2010 Oct 27; 22(10):1069-e281. PubMed ID: 20524987
    [Abstract] [Full Text] [Related]

  • 15. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M, Chang S, Hellriegel ET.
    Clin Ther; 2009 Jan 27; 31(1):108-14. PubMed ID: 19243711
    [Abstract] [Full Text] [Related]

  • 16. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.
    Lee L, Niu H, Rueger R, Igawa Y, Deutsch J, Ishii N, Mu S, Sakamoto Y, Busse-Reid R, Gimmi C, Goelzer P, De Schepper S, Yoshimura Y, Barrett J, Ishikawa Y, Weissgerber G, Peck R.
    Clin Cancer Res; 2009 Dec 01; 15(23):7368-74. PubMed ID: 19934286
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC.
    Clin Ther; 2009 Aug 01; 31(8):1776-86. PubMed ID: 19808136
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study.
    Sádaba B, Azanza JR, Quetglas EG, Campanero MA, Honorato J, Coronel P, Gimeno M.
    Rev Esp Quimioter; 2007 Mar 01; 20(1):51-60. PubMed ID: 17530036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.